The Asia-Pacific now carries the world’s largest burden of obesity, yet obesity hypoventilation syndrome (OHS) remains under-recognised and often presents late, with acute respiratory failure.
This talk examines whether current diagnostic criteria and screening tools, largely derived from non-Asian populations, serve our patients well. It explores why Asian patients may develop OHS at a lower BMI, how to identify them earlier, and how to choose and optimise PAP therapy. Finally, it considers where bariatric surgery and the new incretin-based therapies fit in a disease that PAP alone does not cure.